Delayed COVID-19 Respiratory Failure in Patients with Lymphoma on Rituximab-based Chemoimmunotherapy

Marc S. Hoffmann, Siddhartha Ganguly

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

• COVID-19 can present with delayed onset of symptoms in patients with lymphoma receiving rituximab-based chemoimmunotherapy. • Despite delayed onset of symptoms with prolonged asymptomatic period, outcomes can be particularly severe, including respiratory failure, thrombotic complications, and death.

Original languageEnglish (US)
Pages (from-to)e548-e550
JournalClinical Lymphoma, Myeloma and Leukemia
Volume21
Issue number6
DOIs
StatePublished - Jun 2021

Keywords

  • COVID-19
  • Chemotherapy
  • Rituximab

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Delayed COVID-19 Respiratory Failure in Patients with Lymphoma on Rituximab-based Chemoimmunotherapy'. Together they form a unique fingerprint.

Cite this